The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CPHI | -25.36% | -99.14% | -61.41% | -100% |
| S&P | +18.37% | +110.18% | +16.02% | +511% |
China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm’s product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.03M | 10.9% |
| Gross Profit | -$0.24M | 78.2% |
| Gross Margin | -23.82% | 97.3% |
| Market Cap | $5.84M | -85.2% |
| Market Cap / Employee | $0.03M | 0.0% |
| Employees | 231 | -3.3% |
| Net Income | -$0.53M | 63.3% |
| EBITDA | -$0.33M | 49.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.63M | -15.5% |
| Accounts Receivable | $0.27M | 5.5% |
| Inventory | 1.7 | -40.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.32M | -5.9% |
| Short Term Debt | $2.11M | -20.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.92% | 3.5% |
| Return On Invested Capital | -48.05% | 26.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.29M | 388.8% |
| Operating Free Cash Flow | $0.29M | 500.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.47 | 6.36 | 10.83 | 0.82 | -81.61% |
| Price to Sales | 0.74 | 1.37 | 2.00 | 1.33 | 107.10% |
| Price to Tangible Book Value | 13.45 | 19.17 | 69.63 | 10.07 | 3.19% |
| Price to Free Cash Flow TTM | 16.39 | - | |||
| Enterprise Value to EBITDA | -18.94 | -12.21 | -27.20 | -26.08 | 131.90% |
| Free Cash Flow Yield | 6.1% | - | |||
| Return on Equity | -75.1% | -61.6% | -59.1% | -52.0% | -30.50% |
| Total Debt | $4.01M | $3.59M | $3.51M | $3.43M | -15.56% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
